Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Investor Relations

Board Committees

Corporate Governance and Nominating Committee

Description of Corporate Governance and Nominating Committee

James O. Armitage, M.D.
Gary W. Pace, Ph.D.
Mani Mohindru, Ph.D.